Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Nuria Chic"'
Autor:
Fara Brasó-Maristany, Pierfranco Conte, Lisa A. Carey, Benedetta Conte, Mei Yin C. Polley, Joon Jeong, Seho Park, Charles M. Perou, Nuria Chic, Gaia Griguolo, Aranzazu Fernandez-Martinez, Soong June Bae, Maria Vittoria Dieci, Aleix Prat, Sung Gwe Ahn, Valentina Guarneri
Publikováno v:
Cancer Research. 81:PS10-02
Background: Patients with HER2+ breast cancer who have residual disease after neoadjuvant anti-HER2 plus chemotherapy have a high risk of recurrence and benefit from adjuvant trastuzumab emtansine (T-DM1). We hypothesize that endocrine-responsive res
Autor:
Laura Mezquita, David Planchard, Ralph Chebib, Nuria Chic, Caroline Caramella, Mihaela Aldea, Benjamin Besse
Publikováno v:
Clinical Lung Cancer. 22:e54-e56
Autor:
Ronald E. Kates, Laura Barberá, Miriam Cuatrecasas, Nadia Harbeck, Oleg Gluz, Fara Brasó-Maristany, Patricia Villagrasa, Tommaso Giarratano, Dolors Soy, Maria Vidal, Tomás Pascual, David Pesantez, Vassilena Tsvetkova, Patricia Galván, Aleix Prat, Hans Kreipe, Laia Paré, Mathias Christgen, Montserrat Muñoz, Barbara Adamo, Inés Monge-Escartín, Blanca Gonzalez-Farre, Maria Vittoria Dieci, D. Martinez, Pierfranco Conte, Tamara Saurí, Valentina Guarneri, Nuria Chic, Gaia Griguolo
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
Cancers, Vol 12, Iss 1902, p 1902 (2020)
Cancers
Volume 12
Issue 7
Universidad de Barcelona
Cancers, Vol 12, Iss 1902, p 1902 (2020)
Cancers
Volume 12
Issue 7
Trastuzumab emtansine (T-DM1) is approved for the treatment of human epidermal growth factor receptor 2 (HER2)-positive (HER2+) metastatic breast cancer (BC) and for residual disease after neoadjuvant therapy
however, not all patients benefit. H
however, not all patients benefit. H
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30b95522a064c1502a80af4150f0652a
http://hdl.handle.net/2445/174260
http://hdl.handle.net/2445/174260
Autor:
Yaroslav Shparyk, Andrew D. Seidman, Yee Soo Chae, Lee S. Schwartzberg, Thomas Wei, Yevhen Hotko, Yen-Shen Lu, Sina Vatandoust, Sara M. Tolaney, Noshir Anthony Dacosta, Sabela Recalde, Chi-Feng Chung, Igor Bondarenko, Hope S. Rugo, Nuria Chic, Patricia Gomez, Joyce O'Shaughnessy, Joe O'Connell, Lawrence Panasci, Gail Lynn Shaw Wright
Publikováno v:
Journal of Clinical Oncology. 39:1061-1061
1061 Research Funding: Odonate Therapeutics, Inc. Background: T is a novel, oral taxane with unique properties, including: oral administration with a low pill burden, a long (8-day) half-life in humans, once-every-3-weeks dosing, no observed hypersen
Autor:
Cristina Teixidó, Patricia Galván, Gisela Riu, Álvaro Urbano, Dolors Soy, Barbara Adamo, Monserrat Muñoz, Blanca Gonzalez-Farre, Gabriela Oses, Tomás Pascual, Aleix Prat, Maria Vidal, Nuria Chic, Sergi Ganau, Laura Oleaga
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
Universidad de Barcelona
Breast cancer is a biologically and clinically heterogeneous disease, and patients with similar clinical stage have markedly different outcomes. Triple-negative breast cancer (TNBC) is defined by the lack of expression of estrogen receptor (ER), prog
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ace071a84784d360ffc85b7fa624cc4a
http://hdl.handle.net/2445/178486
http://hdl.handle.net/2445/178486
Autor:
Andreu Prat, Olga Martínez-Sáez, T. Pascual, Blanca Gonzalez-Farre, A. Rodriguez Hernandez, Nuria Chic, Esther Sanfeliu, R. Moreno, Francesco Schettini, M. Vidal, B. Adamo, Benedetta Conte, Dianny Martínez, Iris Faull, E.M. Ciruelos, Aurelio Rodríguez, Fara Brasó-Maristany, Justin I. Odegaard, Montse Muñoz, Patricia Galván
Publikováno v:
Annals of Oncology. 31:S17